Prodrugs of CL316243: a selective β3-adrenergic receptor agonist for treating obesity and diabetes
- 19 July 1999
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 9 (14) , 1921-1926
- https://doi.org/10.1016/s0960-894x(99)00316-9
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Pharmacological Treatment of Obesity: Therapeutic StrategiesJournal of Medicinal Chemistry, 1999
- Pharmacological characteristics and species‐related variations of β3‐adrenergic receptorsFundamental & Clinical Pharmacology, 1995
- β3 and Atypical β‐AdrenoceptorsMedicinal Research Reviews, 1993
- Disodium (R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316,243). A potent .beta.-adrenergic agonist virtually specific for .beta.3 receptors. A promising antidiabetic and antiobesity agentJournal of Medicinal Chemistry, 1992
- Preparation of 1-acyloxyethyl esters of 7-(2-(2-aminothiazol-4-yl)acetamido)-3-(((1-(2-dimethylaminoethyl)-1H-tetrazol-5-yl)thio)methyl)ceph-3-em-4-carboxylic acid (cefotiam) and their oral absorption in mice.The Journal of Antibiotics, 1986
- AcylalsJournal of the American Chemical Society, 1941